Haoxi Health Technology Ltd Announces $4 Million Registered Direct Offering

Haoxi Health Technology Ltd announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 10,000,000 of the Company’s Class A Ordinary Shares, par value $0.32 per share (or pre-funded warrants in lieu thereof) at a purchase price of $0.40 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.33 per share. The aggregate gross proceeds to the Company of this offering are expected to be approximately $4 million. The transaction is expected to close on or about July 13, 2026, subject to the satisfaction of customary closing conditions. Univest Securities, LLC is acting as the sole placement agent. The registered direct offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-287686) previously filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) and became effective by on June 13, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Univest Securities, LLC at [email protected], or by calling +1 (212) 343-8888.